Early in the course of the disease, the clinical symptoms of autoimmune liver disease are not obvious and the diagnosis is mainly based on a combination of biochemical, immunological, imaging and histopathological features. Since autoimmune liver disease includes autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Therefore, we will introduce each of them in the following. 1, diagnosis of primary biliary cirrhosis (PBC) PBC is a chronic non-suppurative granulomatous cholangitis that mainly affects medium-sized intrahepatic bile ducts, especially intrahepatic interlobular bile ducts, with a prevalence of >400/100,000 and a female susceptibility (over 90%). The majority of patients progress to cirrhosis within 10-30 years and are often diagnosed only at an advanced stage of the disease. Ursodeoxycholic acid (UDCA) can reduce the liver damage caused by cholestasis and slow down the progression of the disease. A diagnosis of “definite” PBC can be made when the combination of cholestatic liver function changes, anti-mitochondrial antibody (AMA) titers >1:40 and corresponding histopathological features are present, while the presence of any two of them is “probable” diagnosis. It is not clear whether a high titer of AMA alone is sufficient to diagnose PBC. The prevalence of AIH is about 170/100,000, mainly in young women, and it often leads to severe hepatitis manifestations and can progress rapidly to cirrhosis. Elevated serum transaminase levels, interfacial hepatitis with or without lobular hepatitis or bridging necrosis of the central-confluent area, and the presence of autoantibodies are the main diagnostic bases. However, these are not sufficient to exclude other causes of liver pathology, such as drug-induced hepatitis and viral infections, as these diseases can also produce corresponding autoantibodies. Therefore, the diagnosis of definitive AIH needs to exclude these conditions. 3. Diagnosis of primary sclerosing cholangitis (PSC) PSC is a progressive cholestatic liver disease with a prevalence of about 130/100,000. Unlike AIH and PBC, PSC mainly affects men and is associated with inflammatory bowel disease in 70% (40% to 98%) of patients. PSC is a progressive disease that leads to destruction of intrahepatic and extrahepatic bold ducts, causing cholestasis, liver fibrosis and cirrhosis. The risk of bile duct cancer is elevated at all stages of the disease. There is no effective treatment available, but there are data that high doses of ursodeoxycholic acid can slow the progression of the disease in some patients.The diagnosis of PSC relies on unique bile duct imaging changes that show intra- and extrahepatic bile duct involvement. However, imaging cannot differentiate between primary and secondary sclerosing cholangitis. Moreover, only small intrahepatic bile ducts are affected in 5% of PSC cases.